Helix BioPharma (OTCMKTS:HBPCF) Announces Quarterly Earnings Results

Helix BioPharma (OTCMKTS:HBPCF) issued its earnings results on Monday. The company reported ($0.02) EPS for the quarter, Zacks reports.

Helix BioPharma Stock Performance

Shares of HBPCF remained flat at $0.60 on Monday. Helix BioPharma has a 52 week low of $0.59 and a 52 week high of $0.60. The business’s 50-day moving average price is $0.56 and its 200-day moving average price is $0.49. The stock has a market capitalization of $31.81 million, a PE ratio of -6.00 and a beta of -0.22.

Helix BioPharma Company Profile

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.